Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $380
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth has maintained an Overweight rating on United Therapeutics and increased the price target from $350 to $380.
August 20, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has reaffirmed its Overweight rating on United Therapeutics and increased the price target to $380, indicating confidence in the company's future performance.
The increase in price target from $350 to $380 by Wells Fargo suggests a positive outlook on United Therapeutics' future performance. The Overweight rating indicates that the analyst expects the stock to outperform the average total return of stocks in the analyst's coverage universe over the next 12 months.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100